Precision metabolome reprogramming for imprecision therapeutics in retinitis pigmentosa

11Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Retinitis pigmentosa (RP), the most common form of rod-cone dystrophy, is caused by greater than 3100 mutations in more than 71 genes, many of which are preferentially expressed in rod photoreceptors. Cone death generally follows rod loss regardless of the underlying pathogenic mutation. Preventing the secondary loss of cone photoreceptors would preserve central visual acuity and substantially improve patients’ quality of life. In this issue of the JCI, Wang et al. demonstrate that adeno-associated virus–mediated overexpression of TGF-β1 promoted cone survival and function in 3 distinct RP models with rod-specific mutations. TGF-β1 induces microglia to metabolically tune from a glycolytic phenotype (M1) to an oxidative phenotype (M2), which associates with neuroprotection and the antiinflammatory ecosystem. Consolidating the results of this study with our current understanding of how TGF-β1 regulates microglia polarization, we highlight cell-specific metabolome reprogramming as a promising non–gene-specific therapeutic avenue for inherited retinal degenerations.

Cite

CITATION STYLE

APA

Caruso, S., Ryu, J., Quinn, P. M. J., & Tsang, S. H. (2020, August 3). Precision metabolome reprogramming for imprecision therapeutics in retinitis pigmentosa. Journal of Clinical Investigation. American Society for Clinical Investigation. https://doi.org/10.1172/JCI139239

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free